Pulmonary Arterial Hypertension

Oral Selexipag Offers New Therapy Option in PAH-CHD, Case Reports Show

May 18th 2021, 8:40pm


A series of 5 cases highlights different opportunities to incorporate selexipag into the care of patients with pulmonary arterial hypertension, potentially eliminating risks associated with parenteral prostacyclin.

New Analysis Identifies Prognostic Indicators in Pulmonary Hypertension Secondary to HFrEF

May 13th 2021, 10:30am


Right ventricular end-systolic elastance to end-systolic arterial elastance coupling in excess of 0.68 was linked with preserved right ventricular function and better survival outcomes in patients with heart failure with reduced ejection fraction and secondary pulmonary hypertension.

Study: Inhaled Levosimendan Non-Inferior to IV Administration in Pediatric Surgery

May 7th 2021, 6:35pm


In a first-of-its kind study, young children undergoing heart surgery had similar results regardless of whether they received levosimendan intravenously or via inhalation.

Monotherapy or Combo Therapy for Older Patients With PAH and Multiple Comorbidities?

April 30th 2021, 1:00pm


Patients with pulmonary arterial hypertension (PAH) who have comorbidities or advanced age who are treated with a monotherapy have comparable outcomes to patients on combination therapies.

Text Messages Can Successfully Increase Step Counts for Patients With PAH

April 27th 2021, 1:30pm


A text message–based intervention successfully increased step counts for patients with pulmonary arterial hypertension (PAH).

Patients With PAH Can Safely Transition From Bosentan and Sildenafil to Alternative Therapy

April 21st 2021, 1:30pm


While bosentan and sildenafil is a common combination therapy in patients with pulmonary arterial hypertension (PAH), patients may need to transition to alternative therapy because of the potential for drug-drug interactions with this combination.

Educational Support Can Improve Compliance to Oral PAH Therapies

April 18th 2021, 1:15pm


An educational nursing program can positively impact medication compliance in patients receiving oral pulmonary arterial hypertension (PAH) therapies.

PAH Treatment Patterns and Costs Related to Hospitalization

April 15th 2021, 1:45pm


New research presented at AMCP 2021, the annual meeting of the Academy of Managed Care Pharmacy, evaluated treatment patterns and costs related to hospitalization for patients with pulmonary arterial hypertension (PAH).

Better Understanding of Potential Genetic Mutations May Lead to Improved PAH Diagnosis, Treatment

April 13th 2021, 4:25pm


A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.

Assessing Nutritional Risk Can Predict PAH Prognosis at First Hospitalization

April 6th 2021, 9:28pm


Adjunct nutritional therapies may be a simple way to improve the prognosis for patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension who are hospitalized.